{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:58:24Z","timestamp":1781272704739,"version":"3.54.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Utilization of novel Bruton tyrosine kinase inhibitors (BTKi) has become common for treating CLL\/SLL patients, yet limited evidence exists on the clinical characteristics and outcomes following BTKi therapy discontinuation in China. This multicenter retrospective study analyzed 37 CLL\/SLL patients in China who discontinued BTKi therapy. The mean age at discontinuation was 62.67 years, with the majority being male (67.57%). Most patients (62.16%) were relapsed\/refractory (R\/R) CLL\/SLL patients prior to BTKi treatment, and 37.84% were treatment-na\u00efve patients. Treatment-na\u00efve patients were significantly younger than R\/R patients (56.93 vs. 66.16 years,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.005). Discontinuation reasons included resistance (48.65%), intolerance (32.43%), and other factors (18.92%). The most frequently used regimen among the post-BTKi first subsequent therapies was the anti-CD20 antibody combination therapy (52.90%). The overall disease control rate during BTKi treatment was 78.13%. The median progression-free survival (PFS) for BTKi therapy was 19.09 months, 19.09 months for treatment-na\u00efve patients, and 14.39 months for R\/R patients. The minimum median PFS was observed in patients with resistance (7.86 months). After BTKi discontinuation, median PFS was shorter: 8.87 months for first subsequent therapy and 5.32 months for second subsequent therapy. No significant difference was observed in overall survival. These findings illustrate the impact of prior treatment and discontinuation reasons on subsequent outcomes.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1739102","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:21:19Z","timestamp":1781270479000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease characteristics, treatment, and outcomes in Chinese chronic lymphocytic leukemia patients following BTK inhibitor discontinuation: a multicenter real-world study"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuting","family":"Yan","sequence":"first","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Haematology, The Affiliated Hospital of Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Haematology, First Affiliated Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Haematology, The Affiliated Hospital of Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Haematology, First Affiliated Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyang","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahuang","family":"Lin","sequence":"additional","affiliation":[{"name":"Epidemiology Asia Pacific Unit, Biostatistics and Research Decision Sciences (BARDS), MSD R&D (China) Co., Ltd","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqun","family":"Fu","sequence":"additional","affiliation":[{"name":"Epidemiology Asia Pacific Unit, Biostatistics and Research Decision Sciences (BARDS), MSD R&D (China) Co., Ltd","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","place":["Tianjin, China"]},{"name":"Tianjin Institutes of Health Science","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"622","DOI":"10.6004\/jnccn.2022.0031","article-title":"NCCN guidelines\u00ae insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 3","volume":"20","author":"Wierda","year":"2022","journal-title":"J Natl Compr Canc Netw."},{"key":"B2","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3760\/cma.j.issn.0253-2727.2022.07.001","article-title":"The guideline of the diagnosis and treatment of mantle cell lymphoma in China","volume":"14","author":"Qiu","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B3","doi-asserted-by":"publisher","first-page":"840616","DOI":"10.3389\/fonc.2022.840616","article-title":"Trends in disease burden of chronic lymphocytic leukemia at the global, regional, and national levels from 1990 to 2019, and projections until 2030: a population-based epidemiologic study","volume":"12","author":"Ou","year":"2022","journal-title":"Front Oncol."},{"key":"B4","article-title":"Chronic Lymphocytic Leukemia","author":"Master","year":"2023"},{"key":"B5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.21147\/j.issn.1000-9604.2019.04.01","volume":"31","year":"2019","journal-title":"Chin J Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.leukres.2018.08.011","article-title":"Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China?","volume":"73","author":"Yang","year":"2018","journal-title":"Leuk Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"885150","DOI":"10.3389\/fonc.2022.885150","article-title":"Distinct age-related clinical features and risk assessment in Chinese with chronic lymphocytic leukemia","volume":"12","author":"Tian","year":"2022","journal-title":"Front Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"Jama."},{"key":"B11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.21147\/j.issn.1000-9604.2021.03.01","article-title":"Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)","volume":"33","author":"Zhu","year":"2021","journal-title":"Chin J Cancer Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica."},{"key":"B13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41571-018-0037-8","article-title":"Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy","volume":"15","author":"Burger","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1158\/1078-0432.CCR-14-2225","article-title":"FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukemia","volume":"21","author":"de Claro","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.3390\/molecules28052400","article-title":"Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of preclinical studies and evaluation of clinical trials","volume":"28","author":"Rozkiewicz","year":"2023","journal-title":"Molecules."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/cam4.1337","article-title":"Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study","volume":"7","author":"Huang","year":"2018","journal-title":"Cancer Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.17219\/acem\/99911","article-title":"Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: a report from the Polish Adult Leukemia Study Group (PALG)","volume":"28","author":"Iskierka-Ja\u017cd\u017cewska","year":"2019","journal-title":"Adv Clin Exp Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib treatment for first-line and relapsed\/ refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study","volume":"26","author":"Byrd","year":"2020","journal-title":"Am Assoc Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/ejh.13499","article-title":"Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"105","author":"Aarup","year":"2020","journal-title":"Eur J Haematol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.2217\/fon-2021-0964","article-title":"Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia","volume":"17","author":"Hou","year":"2021","journal-title":"Future Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ajh.25436","article-title":"Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: phase 3 analysis","volume":"94","author":"O'Brien","year":"2019","journal-title":"Am J Hematol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/jha2.322","article-title":"Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center","volume":"3","author":"Ranti","year":"2022","journal-title":"eJHaem."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica."},{"key":"B24","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2040620721989588","DOI":"10.1177\/2040620721989588","article-title":"The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia","volume":"12","author":"Gordon","year":"2021","journal-title":"Ther Adv Hematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"107372","DOI":"10.1016\/j.leukres.2023.107372","article-title":"Canadian evidence-based guideline for treatment of relapsed\/refractory chronic lymphocytic leukemia","volume":"133","author":"Owen","year":"2023","journal-title":"Leuk Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.3390\/cancers15071996","article-title":"Efficacy and safety of Bruton tyrosine kinase inhibitor monotherapy compared with combination therapy for chronic lymphocytic leukemia and small lymphocytic lymphoma: a systematic review and meta-analysis","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"key":"B29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1097\/CM9.0000000000001811","article-title":"Chronic lymphocytic leukemia in China","volume":"135","author":"Gale","year":"2022","journal-title":"Chin Med J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1080\/16078454.2020.1833504","article-title":"Real-world analysis of treatment patterns and clinical outcomes in patients with newly diagnosed chronic lymphocytic leukemia from seven Latin American countries","volume":"25","author":"Chiattone","year":"2020","journal-title":"Hematology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"797","DOI":"10.3324\/haematol.2018.200204","article-title":"First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013","volume":"104","author":"Sylvan","year":"2019","journal-title":"Haematologica."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/cam4.1396","article-title":"NOTCH1 mutation and its prognostic significance in Chinese chronic lymphocytic leukemia: a retrospective study of 317 cases","volume":"7","author":"Zou","year":"2018","journal-title":"Cancer Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-023-01469-7","article-title":"Unresolved questions in selection of therapies for treatment-na\u00efve chronic lymphocytic leukemia","volume":"16","author":"Bennett","year":"2023","journal-title":"J Hematol Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood."},{"key":"B35","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2147\/BLCTT.S326627","article-title":"Use of BTK inhibitors in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma (CLL\/SLL): a practical guidance","volume":"12","author":"St-Pierre","year":"2022","journal-title":"Blood Lymphat Cancer."},{"key":"B36","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s11899-023-00700-z","article-title":"Relapsed\/Refractory Chronic Lymphocytic Leukemia (CLL)","volume":"18","author":"Odetola","year":"2023","journal-title":"Curr Hematol Malig Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1182\/hematology.2022000344","article-title":"Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax","volume":"2022","author":"Scarf\u00f2","year":"2022","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1182\/bloodadvances.2019001204","article-title":"Is a BTKi or BCL2i preferable for first \u201cnovel\u201d therapy in CLL? The case for BTKis","volume":"6","author":"Brem","year":"2022","journal-title":"Blood Adv."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1739102\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T13:21:21Z","timestamp":1781270481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1739102\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":39,"alternative-id":["10.3389\/fmed.2026.1739102"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1739102","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1739102"}}